Our findings identified inhibitors of the phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway, one of the most aberrantly regulated cellular pathways in cancer [17,18], as novel candidate drugs to treat NB patients with hypoxic tumors. This evidence concerns the gene AKT1 and cancer.